Four additional posters presented at the meeting highlighted recently released results from a placebo-controlled Phase 3 study conducted in abdominal surgery patients, new pharmacokinetic data from a study evaluating different oral-transmucosal routes of delivery of sufentanil NanoTabs, design features for the NanoTab System, and new data from three Human Factors studies describing ease of set-up and use of the NanoTab System for patients and healthcare personnel.
"We have significant data to present at meetings during the next year based on the ongoing analysis of our recent clinical trials," stated Dr. Mike Royal , chief, clinical affairs for AcelRx. "The well-published high therapeutic index for sufentanil and its short brain equilibration time is being reinforced by the clinical data that we are collecting," added Dr. Royal.
"We are excited to present this additional data at the ASRA meeting regarding our NanoTab System. We are particularly pleased by the rapid reduction in pain intensity after treatment is started, and the reduced number of patients experiencing oxygen desaturation events, an important safety measure, when using the NanoTab System," stated Richard King , president and CEO of AcelRx. "We remain on track to submit an NDA for the NanoTab System later this year."
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA
|SOURCE AcelRx Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved